The anti-cancer effectiveness of some heterocyclic compounds containing sulfur atom

Sulfur-contained heterocyclic compounds have gained great attention due to their potential anti-cancer properties. These compounds are diverse, having several modes of actions, and are expected to have a greater role in treating different cancer states. Currently, medicinal chemistry has impacted the identification and improvement of these heterocycles in a number of ways. This is mainly in enzyme and cell culture assays, because they are capable of inactivating the repair mechanisms required for cell survival or growth. The compounds-mostly examples being sulforaphane (as an isothiocyanate) and thiophene derivatives-have shown highly significant anti-cancer activities in both preclinical screens and early clinical trials. These findings are establishing growing hopes that these compounds will become powerful gears of anti-cancer therapy for effective frustration of desirable disease targets. The strategy of structure-activity relationships (SARs) has been very proactive in enhancing the activity and specificity of compounds through molecular modifications, making it simpler for the design of highly selective and efficacious therapeutics, leaving alone barriers posed by factors such as drug resistance and adverse effects. On the other hand, a few sulfur-containing heterocycles have reached at least a clinical trial stage, showing a good margin of safety, alongside encouraging efficacy against cancers including breast, lung, and colorectal cancer types. This review aims to delve a little more into the anti-cancer build-up of sulfur-containing heterocycles, explaining the mechanism of action, SAR findings, and recent development in their clinical application. Should this review be a guide to future research based on the articles already published, it will be the first step toward fostering new target-based agents against cancer, as well as boosting the terrain itself.